INTRODUCTION AND OBJECTIVES: Over 1,500 bladder cancers were diagnosed among U.S. Veterans in 2010, the majority of which were non-muscle invasive bladder cancer (NMIBC). Little is known about NMIBC treatment within the Veterans Affairs (VA) health system. Our objective was to describe the quality of care for Veterans with newly diagnosed NMIBC within Veterans Integrated Service Network (VISN) 2.
INTRODUCTION AND OBJECTIVES: Over 1,500 bladder cancers were diagnosed among U.S. Veterans in 2010, the majority of which were non-muscle invasive bladder cancer (NMIBC). Little is known about NMIBC treatment within the Veterans Affairs (VA) health system. Our objective was to describe the quality of care for Veterans with newly diagnosed NMIBC within Veterans Integrated Service Network (VISN) 2.
METHODS: ICD-9/10 codes were used to identify patients in VISN 2 with newly-diagnosed bladder cancer from 1/2016-8/2017. We collected data on diagnostic transurethral resection of bladder tumor (TURBT), and induction and maintenance intravesical therapies (IVT). We assigned NMIBC-risk groups according to the AUA guidelines and used operative notes to estimate tumor size and focality. Our primary objectives were percentage of TURBTs that contained muscle, the use of upper tract imaging at diagnosis, high-risk NMIBC treated with induction IVT, and the use of maintenance IVT when indicated. We performed logistic regression to test if distance to diagnosing VA was associated with receipt of induction IVT.
RESULTS: We identified 140 newly diagnosed patients (Table 1 ). 79% received appropriate upper tract imaging. 86% had NMIBC of whom 16% were low-risk, 28% intermediate-risk, and 56% high-risk. Detrusor was present in the initial TURBT in 80% (97/121) of all NMIBC patients and 84% (57/68) of high-risk patients. Repeat TURBT was performed in 62% (32/52) of patients with any T1 disease and 56% (38/68) of high-risk disease. Induction IVT was given to 0% of low-risk, 24% of intermediate-risk, and 66% of highrisk patients. 7 patient charts were not accessible to review maintenance IVT. In the accessible charts, 59% (24/41) of high-risk patients responded to induction BCG and 54% (13) of them were placed on maintenance BCG. On logistic regression, distance to VA was not associated with receipt of induction IVT (OR[0.99, 95% CI 0.97-1.01, p[0.52) after adjusting for age and comorbidities.
CONCLUSIONS: Among Veterans with newly-diagnosed NMIBC in VISN 2, we found detrusor muscle was sampled in the majority of initial TURBTs and observed high utilization of repeat TURBT in T1 NMIBC. Induction IVT was used primarily in high-risk disease and maintenance IVT was given at a relatively similar rate. Further investigation is needed to improve receipt of IVT among VISN 2 patients.
Source of Funding: None

MP43-17 SINGLE SHORT-DURATION INSTILLATION OF PIRARUBICIN FOR LOW RISK NON-MUSCLE INVASIVE BLADDER CANCER: COMPARISON WITH MITOMYCIN C
Shigehisa Kubota*, Tetsuya Yoshida, Susumu Kageyama, Otsu, Japan; Taichi Sano, Ritto, Japan; Takashi Osafune, Uji, Japan; Yuji Sakano, Higashi-Ohmi, Japan; Chul Jang Kim, Kohka, Japan; Akihiro Kawauchi, Otsu, Japan INTRODUCTION AND OBJECTIVES: Pirarubicin (THP) has a high affinity for bladder tumor cells and a short reaction time, thus, short-duration instillation chemotherapy may have a recurrencepreventive effect. No previous study has compared the treatment efficacy of short indwelling time of THP with standard treatments. We evaluated the prophylactic effect of a single short-duration instillation of THP immediately after TURBT for low-risk non-muscle-invasive bladder cancer (NMIBC) compared with that of a standard 60-minute instillation of mitomycin C (MMC).
METHODS: We retrospectively studied the clinical profiles and outcomes of 111 patients with low risk NMIBC who underwent TURBT between 2006-2016. THP (30mg/30ml) was administered into the bladder immediately after TURBT for 15 minutes, or MMC (20mg/20ml) was administrated for 60 minutes; TURBT alone was performed in the control group. We compared the recurrence-free survivals between groups by the Kaplan-Meier method and Cox regression models. RESULTS: Of the 111 patients, 30 were included in the THP group, 23 in the MMC group, and 58 in the control group. The median follow-up period was 27.0 months. The recurrence-free survival (RFS) rates at 1 year and 3 years, respectively, were 89.3% and 85.4% in the THP group, 95.7% and 85.2% in the MMC group, and 73.4% and 59.7% in the control group (p[0.011, Fig.) . A multivariable Cox regression analysis showed that the instillation of THP and MMC were independently associated with a significant improvement of RFS (Table) .
CONCLUSIONS: A single short-duration instillation of THP for 15 minutes immediately after TURBT significantly prevented intravesical recurrence in low-risk NMIBC patients, and its effect was similar to that of MMC instillation for 60 minutes. This method can be expected to reduce the risk of extravesical leakage of anticancer agents due to hyperextension of the bladder.
Source of Funding: none
MP43-18 DYNAMIC REAL-TIME MICROSCOPY OF BLADDER NEOPLASMS USING CONFOCAL LASER ENDOMICROSCOPY
Yiping Zhu*, Dingwei Ye, Shanghai, China, People's Republic of INTRODUCTION AND OBJECTIVES: Confocal laser endomicroscopy (CLE) enables dynamic imaging of the cellular structures below the mucosal surface and holds promise in providing real time optical diagnosis and grading of urothelial carcinoma. We presented our initial experience using CLE for the diagnosis of urothelial carcinoma of bladder.
METHODS: 21 patients scheduled to undergo transurethral resection of bladder tumors were recruited. One urologist who had already participated in a computer-based training course performed all the CLEs. After standard white light cystoscopy (WLC), fluorescein was administered intravesically as a contrast dye. A 2.6 mm probe based CLE (Cellvizio, Mauna Kea Technologies) was passed through a 26Fr resectoscope to image normal and abnormal appearing areas. The images were collected with 488 nm excitation at 8 to 12 frames per second. The endomicroscopic images were compared with standard hematoxylin and eosin analysis of transurethral resection of bladder tumor specimens.
RESULTS: Of the 21 recruited patients, 1 had no tumor but inflammation, 2 had carcinoma in situ ( CIS), 7 had low grade tumors, 10 had high grade tumors and 1 had a bladder liomyoma. The overall diagnostic accuracy is 80.9% (17/21) combining CLEþ WLC. 1 inflammation was regarded as CIS, 1 low grade tumor was regarded as high grade and 2 high grade tumors were regarded as low grade.
CONCLUSIONS: CLE is an adoptable technology for novice CLE observers after a training session. CLE demonstrated clear differences between normal mucosa and malignant lesions. However, real-time differentiation between low and high grade tumors, inflammation and cancer, can still be challenging.
